Shortening Duration of Antiarrhythmic Medication for SVT in Infants

Tampere University Hospital

Status: Unknown

Conditions: Supraventricular Tachycardia

Treatments: Drug: Amiodarone; Drug: Flecainide; Drug: Propranolol

Study type: Observational

Funder types: Other

Identifiers

NCT04837261

R20113

Details and patient eligibility

About

The infants diagnosed with SVT are treated with antiarrhythmic medication to prevent the recurrence of SVT. This prospective observational cohort study evaluates efficacy and safety of shortening duration of antiarrhythmic medication to four months in infants with SVT. Primary outcome is incidence of recurrent SVT in infants after 4 months of antiarrhythmic medication compared to retrospectively reviewed cohort.

Enrollment: 70 estimated patients

Sex: All

Ages: Under 6 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 6 months or less
• Documented SVT due to AVRT or AVNRT

Exclusion criteria

• Age > 6 months
• Ectopic atrial tachycardia
• Atrial flutter
• Atrial fibrillation
• Permanent junctional reciprocating tachycardia